FDA should have approved a lower dose of Boehringer Ingelheim GMBH’s Pradaxa, safety experts charge in an article published in the British Medical Journal on July 23.
Pradaxa (dabigatran) was approved in October 2010 at a 150 mg twice-daily dose for reducing risk of stroke in atrial...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?